Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events

Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events

Objective: A prominent, safe and efficient therapy for patients with chronic myeloid leukemia (CML) is inhibiting oncogenic protein BCR::ABL1 in a targeted manner with imatinib, a tyrosine kinase inhibitor. A substantial part of patients treated with imatinib report skeletomuscular adverse events af...

Full description

Saved in:
Bibliographic Details
Main Authors: Pavel Burda (Author), Alzbeta Hlavackova (Author), Vendula Polivkova (Author), Nikola Curik (Author), Adam Laznicka (Author), Jitka Krizkova (Author), Jiri Suttnar (Author), Pavel Klener (Author), Katerina Machova Polakova (Author)
Format: Book
Published: Elsevier, 2024-10-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items